Other Science

Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding

Friday, October 30, 2020 - 9:34pm

In addition, Icosavax received $6.5 million from Open Philanthropy to support development of the companys vaccine platform technology and COVID-19 vaccine candidate.

Key Points: 
  • In addition, Icosavax received $6.5 million from Open Philanthropy to support development of the companys vaccine platform technology and COVID-19 vaccine candidate.
  • To enable rapid progress of the companys COVID-19 vaccine candidate to the clinic, Amgen has agreed to manufacture a key intermediate for initial clinical studies.
  • The team at Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.
  • In addition to the COVID-19 vaccine candidate, Icosavax is also advancing IVX-121 into clinical trials as a potential vaccine for respiratory syncytial virus (RSV) for older adults.

5th LifeSciences BC Investor Summit Attracts International Interest

Friday, October 30, 2020 - 6:17pm

LifeSciences BC , a non-profit, industry association which supports the life sciences sector of British Columbia, and Lumira Ventures , a leading North American healthcare venture capital firm, will host the 5th Annual LifeSciences BCs Investor Summit in Vancouver, B.C., virtually on November 2nd and 3rd, 2020.

Key Points: 
  • LifeSciences BC , a non-profit, industry association which supports the life sciences sector of British Columbia, and Lumira Ventures , a leading North American healthcare venture capital firm, will host the 5th Annual LifeSciences BCs Investor Summit in Vancouver, B.C., virtually on November 2nd and 3rd, 2020.
  • At this years Annual Investor Summit, companies from across the life sciences sector are pitching from the following areas: Digital Health, Medical Devices, Medical Technology, Diagnostics, and Biotechnology.
  • Our Annual Investor Summit provides BC companies an important platform and opportunity to make connections to advance their therapeutics and technologies to an audience of seasoned investors.
  • The Association undertakes numerous initiatives including; local, national and international partnerships that help facilitate investment and global partnering opportunities while nurturing economic development in B.C.

Astrotech Announces Closing of $6.2 Million Registered Direct Offering Priced At-the-Market

Friday, October 30, 2020 - 5:11pm

Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,887,906 shares of its common stock at a price of $2.15 per share for aggregate gross proceeds of $6.2 million.

Key Points: 
  • Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,887,906 shares of its common stock at a price of $2.15 per share for aggregate gross proceeds of $6.2 million.
  • The Company intends to use the net proceeds from this offering for continuing operating expenses and working capital.
  • The shares of common stock were offered by Astrotech pursuant to a "shelf" registration statement on Form S-3 (File No.
  • The offering of the securities was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19

Friday, October 30, 2020 - 1:38pm

The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.

Key Points: 
  • The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.
  • The clinical development strategy will focus on evaluating Avigan tablets for early treatment and post-exposure prophylaxis in the community setting.
  • In collaboration with its partners, Appili will design and oversee Phase 3 clinical trials to support regulatory submissions worldwide.
  • In addition, the Company is also testing FUJIFILM Toyama Chemical Inc.s drug Avigan for the potential treatment and prevention of COVID-19.

COVID-19 Takes a Toll on High-Need US Patients, With More Reporting Telehealth’s Adverse Impact, According to InCrowd

Friday, October 30, 2020 - 12:00pm

InCrowd is continually monitoring these trends and vulnerable populations.

Key Points: 
  • InCrowd is continually monitoring these trends and vulnerable populations.
  • Patient audiences include individuals who suffer from diabetes, asthma, high blood pressure, migraines, cancer, multiple sclerosis, and autoimmune illnesses.
  • Despite 72% of high-need patients saying they are currently using telehealth now, only 51% plan to continue use after the need for pandemic precautions subside.
  • Key among them the perception by only 11% of respondents that the Federal government is taking strong precautions to contain COVID-19.

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia

Friday, October 30, 2020 - 12:00pm

We are very excited to enter into this collaboration with AffaMed Therapeutics, which allows us to expand the potential and geographic reach of DEXTENZA and OTX-TIC, said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix.

Key Points: 
  • We are very excited to enter into this collaboration with AffaMed Therapeutics, which allows us to expand the potential and geographic reach of DEXTENZA and OTX-TIC, said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix.
  • Ocular Therapeutix is a leading ophthalmology company, and we are excited to enter into this partnership for the development and commercialization of both DEXTENZA and OTX-TIC, said Dr. Dayao Zhao, Chief Executive Officer of AffaMed Therapeutics.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutix recently completed a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis.

Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers

Friday, October 30, 2020 - 1:00pm

Incyte (Nasdaq:INCY) today announced that the company has again been named a top biopharma employer by Science magazine through its Top Employers Survey of the global pharmaceutical and biotech industry.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that the company has again been named a top biopharma employer by Science magazine through its Top Employers Survey of the global pharmaceutical and biotech industry.
  • This year, Incyte ranked second, marking the third consecutive year the company has been included in the top three on this prestigious industry list.
  • Rankings were determined based on the Science and Science Careers 2020 Top Employers Survey, which polled employees in biotechnology and pharmaceutical industries to identify the 20 best employers and the driving characteristics associated with each company.
  • The complete Top Biotech, Biopharma and Pharma Employers feature, including individual company rankings, can be found in the October 29 print edition of Science, and online at: https://www.sciencemag.org/features/2020/10/top-employers-rapid-response... .

Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020

Thursday, October 29, 2020 - 8:05pm

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that the Company will release its third quarter 2020 financial results after market close on Thursday, Nov. 5, 2020.

Key Points: 
  • Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that the Company will release its third quarter 2020 financial results after market close on Thursday, Nov. 5, 2020.
  • ET that day to discuss the Company's financial results and provide a general business update.
  • The conference call will be webcast live and will be available on the Investors & Media section of the Dicerna website, www.dicerna.com .
  • GalXC is a trademark of Dicerna Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006226/en/